NASDAQ:LXRX - Lexicon Pharmaceuticals, Inc.
$5.58
 $-0.08
-1.41%
4:00PM EDT
2019-04-18
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  LXRX     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 05   203. 85   241. 91  
42 stocks rank:  4. 34 K 1. 44 K 1. 05 K
# analyst opinions:  3. 00   14. 51   13. 97  
mean recommendation:  2. 20   2. 09   2. 01  

quick ratio:  4. 52   5. 27   1. 81  
current ratio:  4. 72   5. 62   2. 25  

target price low:  10. 00   84. 80   115. 21  
target price avg:  6. 15   111. 51   137. 51  
target price high:  3. 40   135. 81   157. 84  
1-yr high:  13. 69   114. 23   138. 78  
last close:  5. 58   87. 66   116. 69  
50-day avg:  6. 06   95. 54   123. 44  
200-day avg:  8. 37   94. 25   121. 11  
1-yr low:  4. 36   72. 78   98. 34  
volume:  620. 77 K 4. 11 M 8. 07 M
50-day avg volume:  923. 88 K 2. 76 M 5. 02 M
200-day avg volume:  612. 08 K 2. 92 M 4. 59 M

1-day return:  -1. 41 % -0. 41 % 0. 07 %
this week return:  -8. 07 % -5. 74 % -4. 11 %
12-wk return:  25. 11 % 1. 61 % -0. 05 %
52-wk return:  -31. 39 % 3. 12 % 8. 78 %

enterprise value (EV):  677. 95 M 48. 94 B 114. 64 B
market cap:  593. 00 M 43. 07 B 104. 73 B
EBITDA:  -101. 40 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -6. 69   4. 22   12. 73  
enterprise/revenue (EV/R):  10. 72   63. 17   12. 84  
total revenue:  63. 21 M 10. 62 B 38. 47 B
total debt:  245. 00 M 12. 24 B 16. 73 B
net income (common):  -120. 55 M 2. 20 B 4. 20 B

shares outstanding:  106. 27 M 571. 70 M 1. 24 B
shares:  105. 82 M 571. 81 M 1. 23 B
shares short:  10. 00 M 10. 17 M 13. 00 M
shares short prior month:  8. 03 M 9. 54 M 17. 33 M
short ratio:  7. 42   5. 41   3. 28  
short % of float:  38. 06 % 5. 45 % 2. 38 %
total cash/share:  1. 51   11. 14   9. 33  
total cash:  160. 05 M 6. 71 B 7. 15 B
free cash flow:  -118. 74 M 3. 58 B 2. 96 B
operating cash flow:  -148. 61 M 4. 15 B 4. 30 B

book value:  -0. 25   12. 78   26. 92  
price/book:  -22. 41   3. 06   -1. 74  
gross profits:  -39. 52 M 8. 04 B 34. 86 B
operating margins:  -163. 39 % -725. 35 % -89. 04 %
EBITDA margins:  -160. 41 % 10. 94 % 22. 51 %
profit margins:  -190. 71 % 7. 81 % 10. 57 %
gross margins:  -62. 53 % 37. 08 % 55. 70 %

1-yr max volatility:  28. 01 % --- ---
1-yr mean volatility:  -0. 07 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 14   2. 40   4. 10  
forward EPS:  -0. 65   3. 97   7. 13  
P/E:  -4. 90   13. 63   22. 72  
forward P/E:  -8. 58   -15. 95   13. 99  
PE/G:  0. 10   -1. 65   -1. 32  
growth:  -49. 40 % 127. 12 % 29. 61 %
earnings high:  -0. 18   1. 00   1. 66  
earnings avg:  -0. 22   0. 77   1. 53  
earnings low:  -0. 25   0. 50   1. 39  
revenue high:  16. 60 M 2. 68 B 10. 78 B
revenue avg:  13. 27 M 2. 59 B 10. 57 B
revenue low:  10. 00 M 2. 49 B 10. 36 B
return on assets:  -17. 91 % -2. 75 % 4. 55 %
return on equity:  -575. 96 % -18. 45 % 5. 46 %
revenue growth:  -49. 40 % 92. 86 % 18. 96 %
revenue/share:  0. 60   13. 29   55. 46  

beta (1yr vs S&P500):  1. 73   1. 25   0. 93  
sharpe (1yr):  -0. 24   0. 37   0. 70  

held % insiders:  0. 40 % 6. 39 % 3. 38 %
held % institutions:  101. 30 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : LXRX
.    + 1.223 =         1.223 :: INITIAL WEIGHT
.   + 30.292 =        31.516 :: spline projection addition
.    x 1.431 =        45.112 :: industry recommendation factor
.    x 1.901 =        85.759 :: symbol recommendation factor
.     x 1.17 =       100.318 :: EV/R factor
.    x 0.998 =       100.138 :: return on assets factor
.    x 0.942 =         94.37 :: return on equity factor
.    x 0.995 =        93.904 :: revenue growth factor
.    x 2.839 =       266.549 :: current ratio factor
.    x 1.133 =       302.085 :: quick ratio factor
.    x 1.065 =       321.798 :: short ratio factor
.    x 1.776 =       571.482 :: price-to-book factor
.    x 2.089 =      1193.819 :: P/E weight
.    x 1.782 =      2127.368 :: PE/G factor
.     x 1.26 =      2679.451 :: beta factor
.    x 0.238 =       637.349 :: sharpe factor
.    x 1.981 =      1262.694 :: target low factor
.    x 1.107 =      1397.563 :: target mean factor
.    x 0.937 =      1310.209 :: target high factor
.     x 1.31 =      1716.226 :: industry 2-weeks return factor
.    x 0.816 =      1400.529 :: overall "drift" factor
.     x 0.72 =      1008.275 :: largest single-day jump factor
.    x 0.086 =         86.92 :: low price factor
.      x 1.0 =        86.906 :: factor hist industry gain for week 16
.   cubeRoot =         4.429 :: reduced to standardize
.   - 23.168 =         0.054 :: add/subtract for performance
.                      0.054 :: FINAL WEIGHT for NASDAQ:LXRX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org